NASDAQ:ARWR Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis $58.02 -0.34 (-0.58%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$58.06 +0.04 (+0.08%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ARWR alerts:Sign Up Key Stats Today's Range$56.56▼$58.4050-Day Range$55.90▼$89.4152-Week Range$36.88▼$95.49Volume871,718 shsAverage Volume1.92 million shsMarket Capitalization$8.17 billionP/E RatioN/ADividend YieldN/APrice Target$99.07Consensus RatingModerate Buy Company Overview Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing medicines that silence disease-causing genes using RNA interference (RNAi). The company’s proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi-based therapies to specific tissues and reduce the production of targeted proteins. Arrowhead’s research and development programs address a range of conditions, including cardiometabolic, pulmonary, liver, and central nervous system diseases. Its pipeline has included investigational therapies designed to treat disorders such as hypertriglyceridemia, liver disease, respiratory illness, and other conditions. The company’s products remain primarily in clinical development, and its programs have included collaborations and licensing arrangements with larger pharmaceutical companies. Founded in 2003, Arrowhead Pharmaceuticals is headquartered in Pasadena, California. Christopher Anzalone, Ph.D., serves as the company’s president and chief executive officer. Arrowhead’s operations are primarily focused on research, clinical development, and partnerships intended to advance RNAi medicines for patients in the United States and international markets.AI Generated. May Contain Errors. Read More Arrowhead Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreARWR MarketRank™: 2.719580983075 of 5 starsArrowhead Pharmaceuticals scored higher than 54% of companies evaluated by MarketBeat, and ranked 516th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingArrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 1 strong buy rating, 10 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialArrowhead Pharmaceuticals has a consensus price target of $99.07, representing about 70.8% upside from its current price of $58.02.Amount of Analyst CoverageArrowhead Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arrowhead Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($3.62) to ($4.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arrowhead Pharmaceuticals is -25.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arrowhead Pharmaceuticals is -25.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArrowhead Pharmaceuticals has a P/B Ratio of 15.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arrowhead Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.92% of the float of Arrowhead Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 4.03.Change versus previous monthShort interest in Arrowhead Pharmaceuticals has recently increased by 16.05%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArrowhead Pharmaceuticals does not currently pay a dividend.Dividend GrowthArrowhead Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.59 News SentimentArrowhead Pharmaceuticals has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Arrowhead Pharmaceuticals this week, compared to 8 articles on an average week.Search InterestOnly 2 people have searched for ARWR on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.MarketBeat Follows10 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arrowhead Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,186,600.00 in company stock.Percentage Held by Insiders3.60% of the stock of Arrowhead Pharmaceuticals is held by insiders.Percentage Held by Institutions62.61% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arrowhead Pharmaceuticals' insider trading history. Receive ARWR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARWR Stock News HeadlinesArrowhead Pharmaceuticals And 2 Biotech Stocks To OwnOctober 24 at 1:26 AM | finance.yahoo.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Now Rated "Moderate Buy" by Sell-Side AnalystsOctober 23 at 2:29 AM | americanbankingnews.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. | Porter & Company (Ad)FY2031 Earnings Forecast for ARWR Issued By HC WainwrightOctober 18, 2026 | americanbankingnews.comArrowhead Pharmaceuticals (ARWR) Gets a Buy from Piper SandlerOctober 17, 2026 | theglobeandmail.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Rating Reaffirmed as "Buy" by Chardan CapitalOctober 17, 2026 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)October 17, 2026 | americanbankingnews.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Picked Up by Analysts at UBS GroupOctober 17, 2026 | americanbankingnews.comSee More Headlines ARWR Stock Analysis - Frequently Asked Questions How have ARWR shares performed this year? Arrowhead Pharmaceuticals' stock was trading at $66.39 at the beginning of the year. Since then, ARWR shares have decreased by 12.6% and is now trading at $58.02. How were Arrowhead Pharmaceuticals' earnings last quarter? Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) issued its earnings results on Tuesday, August, 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.23) by $0.13. Arrowhead Pharmaceuticals's revenue for the quarter was up 171.0% compared to the same quarter last year. Read the conference call transcript. Who are Arrowhead Pharmaceuticals' major shareholders? Top institutional shareholders of Arrowhead Pharmaceuticals include Pinnacle Associates Ltd. (0.13%), Washington Trust Advisors Inc. (0.05%), Yousif Capital Management LLC (0.03%) and Prime Capital Investment Advisors LLC (0.01%). Insiders that own company stock include Christopher Richard Anzalone, Patrick O'brien, Kenneth Allen Myszkowski, James C Hamilton, Daniel Joseph Apel, Martin Javier San, Douglas B Given, Tracie Oliver, Michael S Perry, Mauro Ferrari, William D Waddill, Hongbo Lu, Victoria Vakiener and Adeoye Y Olukotun. View institutional ownership trends. How do I buy shares of Arrowhead Pharmaceuticals? Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arrowhead Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arrowhead Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Bristol Myers Squibb (BMY), Gilead Sciences (GILD) and AbbVie (ABBV). Company Calendar Last Earnings8/04/2026Today10/25/2026Next Earnings (Estimated)11/24/2026Fiscal Year End9/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, ARWR's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ARWR CIK879407 Webwww.arrowheadpharma.com Phone(626) 696-4702Fax626-304-3401Employees711Year Founded2001Price Target and Rating Average Price Target for Arrowhead Pharmaceuticals$99.07 High Price Target$126.00 Low Price Target$46.00 Potential Upside/Downside+70.8%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($2.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.63 million Net Margins-47.79% Pretax Margin-37.65% Return on Equity-60.06% Return on Assets-17.37% Debt Debt-to-Equity Ratio1.77 Current Ratio5.90 Quick Ratio5.90 Sales & Book Value Annual Sales$669.50 million Price / Sales12.21 Cash Flow$0.12 per share Price / Cash Flow485.93 Book Value$3.64 per share Price / Book15.94Miscellaneous Outstanding Shares140,857,000Free Float135,786,000Market Cap$8.17 billion OptionableOptionable Beta1.29 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:ARWR) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredStill haven't grabbed your midterm report?The Midterm Election Playbook normally sells for 29.97, but it is free today. With the midterms just weeks ...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredAsk a 20 Year Trading Pro Your Stock Questions Live for 5Ross Givens, a market analyst with over 20 years on Wall Street, goes live every Monday at 9 AM ET to break do...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
